Join the Attention-Deficit Hyperactivity Disorder (ADHD) group to help and get support from people like you.
Attention-Deficit Hyperactivity Disorder (ADHD) News (Page 4)
Related terms: ADHD, Attention Deficit Disorder, Childhood hyperkinesis, ADD
Preteen Screen Time Can Affect Adolescent Mental Health
THURSDAY, Oct. 10, 2024 – More screen time in preteens is prospectively associated with later mental health disorders in adolescence, according to a study published online Oct. 7 in BMC Public ...
About 6% of U.S. Adults Have ADHD, Drug Shortages Are Affecting Treatment
THURSDAY, Oct. 10, 2024 – More than 15.5 million U.S. adults have been diagnosed with ADHD, and nearly three-quarters of those taking medication to treat it say drug shortages are hampering their...
Digital Mental Health Games Improve Psychological Outcomes in Youth
THURSDAY, Sept. 26, 2024 – Gamified digital mental health interventions (DMHIs) may offer benefits for youth with attention-deficit/hyperactivity disorder (ADHD) or depressive disorder, according to...
Partner's Adult ADHD Can Harm a Woman's Mental Health
MONDAY, Sept. 23, 2024 – Having a husband or boyfriend with adult ADHD can harm a woman's mental stability, a new study suggests. About 3 in 5 women (59%) with male partners with...
Childhood ADHD Tied to Lower Cognitive Performance in Adulthood
MONDAY, Sept. 23, 2024 – Childhood attention-deficit/hyperactivity disorder (ADHD) is associated with impaired cognitive functioning in adulthood, according to a study published online Aug. 28...
Wildfire Smoke Might Harm Children's Mental Health
TUESDAY, Sept. 17, 2024 – As wildfires continue to burn across parts of California, a new study finds that smoke from these blazes and other air pollution could be harming kids’ mental health. R...
High Doses of ADHD Meds Could Trigger Psychosis
THURSDAY, Sept. 12, 2024 – Prescriptions for amphetamine stimulants to treat ADHD have increased significantly in recent years, particularly during the pandemic. Unfortunately, high doses of...
Amid Shortages, U.S. Allows Expanded Production of ADHD Drug Vyvanse
THURSDAY, Sept. 5, 2024 – The maker of the ADHD drug Vyvanse has been given approval by the U.S. Drug Enforcement Administration to make more of the medication as a shortage of the critical drugs...
FDA Approves Onyda XR (clonidine hydrochloride) Non-Stimulant Liquid Treatment for ADHD
May 29, 2024 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological dis...
FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions
What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...
Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) – Supernus...
FDA Approves Xelstrym (dextroamphetamine) Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
Miami, FL and Jersey City, NJ - March 23, 2022 --Noven Pharmaceuticals, Inc., awholly-ownedsubsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that the U.S. Food and Drug Administration...
Tris Pharma Announces FDA Approval of Dyanavel XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD
In a clinical study in adults, Dyanavel XR tablets demonstrated bioequivalence to Dyanavel XR (amphetamine) extended-release oral suspension. ADHD patients taking Dyanavel XR oral suspension can...
FDA Approves Qelbree (viloxazine) for the Treatment of ADHD
ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...
FDA Approves Azstarys (serdexmethylphenidate and dexmethylphenidate) Capsules for the Once-Daily Treatment for ADHD
CELEBRATION, Fla., March 02, 2021 (GLOBE NEWSWIRE) – KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...
Further information
Related condition support groups
Related drug support groups
Adderall, bupropion, Vyvanse, amphetamine, Adderall XR, Concerta, methamphetamine, Ritalin, Strattera, view more... clonidine, methylphenidate, modafinil, dextroamphetamine, amphetamine / dextroamphetamine, guanfacine, amantadine, 5-HTP, desvenlafaxine, Focalin, Focalin XR